Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific OfficerPORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effe ...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the closing of its previously announced public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offe ...

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the pricing of a public offering of an aggregate of 4,000,000 of the Company’s ordinary shares and accompanying warrants to purchase up to 4,000,000 of the Company’s ordinary shares, at a combined public offering price of $0.65 per ...

Decision at the highest levels of appeal in the Medicare process establishes medical necessity of the ReWalk Exoskeleton for enabling paralyzed individuals to stand and walk in everyday environments.MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the recent ruling by an Adminis ...

Lifeward (LFWD) Conference Summary Company Overview - **Company**: Lifeward Limited - **Industry**: Medical Devices, specifically focused on rehabilitation technologies such as exoskeletons and functional electrical stimulation devices Key Points and Arguments Future Growth and Positioning - Lifeward has developed leading innovative technologies aimed at fundamentally changing lives, with a focus on commercialization [4][6] - The company has achieved significant milestones, including Medicare coverage for personal exoskeletons, which positions them for future growth [9][31] Product Portfolio - Lifeward's product lineup includes: - **ReWalk**: A personal exoskeleton for restoring functional walking [12][43] - **AlterG**: An antigravity system for rehabilitation [35][38] - **MyoCycle FES**: A functional electrical stimulation bike for therapy [40][41] - **ReStore Exosuit**: A soft exoskeleton primarily for stroke patients [43][44] Market Access and Reimbursement - The company has made strides in reimbursement coverage, with significant contracts established in the U.S. and Germany [29][31] - Lifeward is focusing on expanding into the commercial market and enhancing relationships with workers' compensation [30][32] Market Size and Potential - The total addressable market for ReWalk in the U.S. is approximately 15,000 eligible candidates, with an additional 2,000 in Germany, indicating a substantial growth opportunity [34] - The company is targeting a broader market with its various products, aiming for profitability through market penetration [34][71] Financial Performance and Path to Profitability - Lifeward expects to achieve revenue between $28 million to $30 million for the current year, with a goal of reaching breakeven at $40 million to $45 million in revenue by 2026 [47][71] - The company has improved gross margins through efficient operations and product mix [48][65] Product Development and Innovation - Lifeward has launched new versions of its products, enhancing user experience with features like smoother movement and better control [18][19][21] - Continuous feedback from users has driven product improvements, emphasizing the importance of user experience in rehabilitation technologies [27][28] Industry Dynamics - The medical device industry is fragmented, presenting opportunities for future consolidation as Lifeward continues to grow and integrate its product lines [46][47] - The company is strategically positioned to leverage its clinic presence to drive referrals and enhance product adoption [67][68] Additional Important Information - Lifeward's products are manufactured in various locations, with ReWalk produced in Israel and other products made in the U.S. [72] - The company has navigated tariff concerns effectively, with protocols in place to mitigate potential impacts [72] This summary encapsulates the key insights from the Lifeward conference, highlighting the company's strategic direction, product offerings, market potential, and financial outlook.

此前在 美敦力（2004–2023） 任职近20年 ，最终担任美洲地区副总裁 ，主导糖尿病家庭护理业务的支付策略与市场准入。其领导的跨职能团队涵盖 销售、临床支 持、健康经济学、报销、客户服务与营销 等关键部门，具备丰富的跨区域管理经验。 | 思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 即将召开： | | | | | | | | 2025年6月12日，首届全球医美科技大会 | | | | | | | | 2025年7月17日，第二届全球医疗科技大会 | | | | | | | | 2025年9月4-5日，第三届全球手术机器人大会 | | | | | | | | 2025年5月19日 ， 康复护理公司 | Lifeward（纳斯达克代码：LFWD） | 宣布任命 | 前美敦力美洲区副总裁Mark Grant 为公司新任 | 总裁兼首席执行官 | ，自 | 2025年6月2日 | | 起正式生效。此次任命标志着Lifeward进入从技术验证向商业增长过渡的关键阶段 ...

Industry veteran brings 30 years of commercial leadership experienceMARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company’s new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward’s outgoing CEO, will ...

Lifeward (LFWD) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -39.39%. A quarter ago, it was expected that this maker of wearable robotic exoskeletons that help paralyzed patients walk would post a loss of $0.20 per share when it actually produced a loss of $0.38, delivering a surprise of - ...

Lifeward (LFWD) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Mike Lawless - CFOLarry Jasinski - CEOBen Haynor - Managing Director Conference Call Participants Yale Jen - Senior Managing Director & Senior Biotech AnalystSwayampakula Ramakanth - Managing Director & Senior Equity Analyst Operator Good day, and welcome to the Q1 twenty twenty five LifeForward, Inc. Earnings Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now ...

Financial Data and Key Metrics Changes - Q1 2025 revenues were $5 million, down $300,000 year on year, but the LIFO business was up year on year [5][12] - On a non-GAAP basis, adjusted operating loss was $4.6 million compared to $5.5 million for the same periods [19] - GAAP gross margin was 42.2% compared to 26.4% in Q1 2024, while non-GAAP adjusted gross margin was 42.2% compared to 33.7% [17][18] Business Line Data and Key Metrics Changes - Revenue from ReWalk robotics products was $1.6 million, while Alter G products generated $3.4 million, with Alter G sales growing by 19% year on year [14] - The number of ReWalk rentals increased to 36, primarily in Germany, indicating strong future sales potential [6][15] - Alter G has shown significant growth of 1970% in the last two quarters [7] Market Data and Key Metrics Changes - The U.S. pipeline has over 120 qualified leads, up over 70% from two quarters ago [6][15] - The company has expanded partnerships with Alter G distributors, including four new business partners [6] Company Strategy and Development Direction - The company is focused on profitable revenue growth, tight expense control, and cash management [5] - A partnership with CoreLife aims to enhance progress in the workers' compensation segment [6] - The company anticipates a sales range of $28 million to $30 million for 2025, with expectations of a reduced operating loss by Q4 [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in future growth based on a strong pipeline and recent FDA approvals [6][20] - The leadership transition is expected to be smooth, with a solid foundation in place for future growth [11] Other Important Information - The company ended Q1 with $5.7 million in cash and equivalents and no debt, raising an additional $500,000 post-quarter [19] - The company is working collaboratively with Medicare Administrative Contractors to improve claims processing predictability [10] Q&A Session Questions and Answers Question: What is the assessment of recent tariff situations? - The company is monitoring the situation closely and has planned for alternatives within the market, with minimal impact expected on the ReWalk production in Israel [25][26] Question: How does the company support its full-year revenue guidance despite lower Q1 revenue? - Confidence is based on strong momentum in the Ultra G product line and a robust pipeline of leads, indicating growth potential [28] Question: Can you elaborate on the ReWalk seven's differences from the previous version? - The ReWalk seven features significant improvements in usability, power, and control, while maintaining a similar price point [36][39] Question: How does the expanded Mylan partnership benefit the commercial sales force? - The partnership allows access to a new segment for home use, leveraging historical data to drive sales [42] Question: What is the market size for workers' compensation in the U.S.? - The workers' compensation market represents about 6% to 7% of the overall market, providing a significant opportunity for growth [47] Question: How has the Alter G acquisition performed? - The integration has stabilized, and recent product launches have shown strong growth, particularly in international markets [54][56]